Investing in Altria: A Reliable Option for Uncertain Markets

Dec.02.2022
Investing in Altria: A Reliable Option for Uncertain Markets
Investors seeking stability can look to tobacco giant Altria Group for reliable dividend income amid market volatility.

The volatile markets we witnessed in 2022 remind us of the importance of stability for investors. Retirees or others seeking dividends may want to consider investing in tobacco giant Altria Group (MO 0.92%) to stabilize their portfolio and put some money in their pockets.


This stock only dropped 4% in 2022 and paid a generous dividend yield of 8.5% to investors. As Wall Street enters 2023 with some uncertainty, the reliability of such a high yield may be more attractive to investors.


Altria may not be a suitable stock for everyone, but this is why those who hold it can sleep well at night knowing their investment is generating reliable dividend income.


During this period, the stock price fell by 32% as a result of Altria's disastrous failure after acquiring a stake in the e-cigarette company Juul for approximately $13 billion in 2018 and subsequently seeing its value evaporate due to regulatory scrutiny.


However, that was then; now, the stock of Altria reflects that mistake, with a price-to-earnings ratio (P/E) just above 9, significantly lower than the median P/E of the stock over the past decade (P/E of 17). This doesn't mean that the stock price can't still go down, but the discount on Altria's long-term fundamentals may provide a safety margin - bad news has already been factored in.


This may be one of the reasons why Altria is holding steady this year. I suspect that if the stock were traded at a higher valuation - for example, above its ten-year average - it would fall further in this bear market.


An 8.5% reliable dividend yield.


Since the 1960s, Americans have known that cigarettes are harmful to your health, but Altria has continued to make more money. In 2012, Altria shipped 136 billion units of tobacco products, while in 2021 they only shipped 95 billion units. However, the operating profit from tobacco products grew from $6.2 billion to $10.4 billion. This highlights Altria's pricing power due to the addictive nature of their products.


For years, these rising prices have supported Altria's financial health, making it a dividend king that has seen 52 consecutive years of increases.


YCharts provides data on the cash dividend payout ratio for MO.


Investors may be worried about the 81% dividend payout ratio, but they should not be overly concerned. Altria's business does not require a lot of capital; it can distribute the majority of profits to shareholders and still operate successfully. While the business may not be exciting, it has proven to be very effective in generating cash for investors.


Resting in an emergency situation.


It appears reasonable to assume that Altria's rinse-and-repeat model of raising prices will not be effective forever, and the management seems to understand this, as evidenced by their investments in Juul and Cronos Group in an attempt to diversify their business. Altria is still working towards creating a future beyond cigarettes, and investors should monitor their progress over the long term. However, if necessary, the company has significant leverage to generate additional cash.


Altria owns a 10% stake in global brewer AB InBev, which, based on today's stock price, is valued at approximately $11 billion. If Altria were to sell this stake, the resulting cash would be roughly one-eighth of Altria's market value, providing ample funds for stock buybacks or debt repayment. Altria could almost entirely pay off the debt it incurred when investing in Juul.


2FIRSTS will continue to track and report on this issue, with updates available on the "2FIRSTSAPP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
BAT Rothmans says it previously considered exiting South Korea's vaping market because of competitive pressure from unregulated products, but is now reassessing conditions following changes to the country's nicotine regulatory framework. Vuse and other BAT vaping products remain available through existing distribution channels. The statement followed a South Korean media report that interpreted BAT's broader withdrawal from selected Vapour markets as a full exit from South Korea. Meanwhile, Philip Morris International launched VEEV inPRIME in the country in June and began expanding distribution to around 14,000 convenience stores and other retail channels in July. The contrasting moves highlight differing investment strategies as South Korea's regulated vaping market evolves.
Aug.14
Michael Olise’s World Cup Locker-Room Photo Puts Nicotine Pouches in the Sports Business Spotlight
Michael Olise’s World Cup Locker-Room Photo Puts Nicotine Pouches in the Sports Business Spotlight
Several European sports outlets have reported on a suspected nicotine pouch seen in French footballer Michael Olise’s locker photo, bringing football’s long-running “snus” culture back into public view and highlighting brand visibility, product classification and public-health debate around nicotine pouches in sports settings.
News
Jun.25 by 2Firsts Perspectives
Product | IQOS ILUMA i REMIX Limited Edition Launches in Japan, Bringing New Design Elements to Heated Tobacco Devices
Product | IQOS ILUMA i REMIX Limited Edition Launches in Japan, Bringing New Design Elements to Heated Tobacco Devices
Philip Morris Japan (PM Japan) has introduced the IQOS ILUMA i REMIX Limited Edition series, including the IQOS ILUMA i Prime REMIX, IQOS ILUMA i REMIX and IQOS ILUMA i ONE REMIX devices. The limited-edition models were officially announced in Japan on June 9, 2026, and began a phased market rollout from June 10. Featuring gradient color designs and visual customization elements, the collection highlights PMI’s continued use of limited editions to enhance brand experience within its heated tobacco portfolio.
Innovation
Jul.21 by 2Firsts Perspectives
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
The Zhengzhou Tobacco Research Institute of China National Tobacco Corporation has filed a patent application for an end-to-end method to analyze the migration and transformation of chemical compounds in heated tobacco products. Using GC-Orbitrap/MS non-targeted analysis, the method compares tobacco substrate and aerosol samples to distinguish compounds transferred directly from the substrate from those newly formed during heating, while also calculating transfer rates. In an example involving nine heated tobacco products, the patent identified 17 newly formed thermal decomposition compounds and 38 transferred compounds.
Aug.13
Product | OXVA Launches ONEO Pro in France, Upgrading Its Open-Pod Platform
Product | OXVA Launches ONEO Pro in France, Upgrading Its Open-Pod Platform
Vape brand OXVA has introduced the ONEO Pro, a refillable open-pod system that entered the French market in July 2026. The device features a 2,100mAh battery, up to 40W output, a 4ml refillable cartridge, multiple coil options and a 0.96-inch color TFT display. The launch reflects continued performance upgrades within the refillable open-pod segment, with brands adding higher capacity, adjustable output and smarter device interaction.
Aug.03